Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. Show more
Location: 100 Nagog Park, Acton, MA, 01720, United States | Website: https://www.insulet.com | Industry: Medical Devices | Sector: Healthcare
Market Cap
20.55B
52 Wk Range
$173.00 - $329.33
Previous Close
$292.01
Open
$292.96
Volume
510,980
Day Range
$289.08 - $293.16
Enterprise Value
22.58B
Cash
1.283B
Avg Qtr Burn
N/A
Insider Ownership
0.29%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|